1. Scrip
  2. >>New Products

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

EU-Wide Staggered Release Planned

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Concept of a human head with a puzzle in the middle.
(Shutterstock)

Eisai plans to launch Leqembi (lecanemab) in Germany and Austria in fiscal year 2025 and will stagger the drug’s launch in other EU countries over the next few years, following the approval of the early Alzheimer’s disease (AD) drug by the European Commission.

Leqembi, which Eisai co-commercializes with Biogen and is already approved for marketing in the US and other countries, became the first amyloid-targeting

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Therapy Areas

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.